Kelun‑Biotech & Crescent Biopharma Partner to Accelerate Bispecific & ADC Cancer Treatments
Kelun‑Biotech partners with Crescent Biopharma to fast‑track bispecific antibody CR‑001 and ADC SKB105, aiming at breakthrough solid‑tumor therapies and stronger market reach in China.
- Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read